FDA Issues Safety Communication for BioZorb Markers and Potential Risks with Use in Breast Tissue

As a result of the ongoing litigation by Jinks Crow, the FDA has issued a safety communication regarding Biozorb® markers and potential risks with use in breast tissue.

Read Full Text of FDA Safety Communication

If you or a loved one was implanted with a Biozorb® device as part of treatment for breast cancer and has experienced any of the above injuries, please contact Jinks Crow & Dickson for a free consultation with an attorney.